Keta Medical Center is excited to share groundbreaking news in the field of mental health. The FDA has officially approved Spravato® (esketamine) as a monotherapy for treatment-resistant depression. This means patients can now benefit from Spravato without the need to pair it with daily oral antidepressants, creating a simpler and more accessible treatment pathway.
Why This Approval Matters
For many patients, the requirement to take additional medications has been a barrier to seeking depression treatment with Spravato. Now, with this new approval, more individuals can explore this innovative therapy as a standalone option. Spravato is known for its rapid symptom relief, with some patients experiencing improvements within 24 hours—a crucial benefit for those who have struggled with traditional treatments.
Nearly all insurance companies have updated their policies to cover Spravato as a monotherapy. Aetna, Medicare, Anthem BCBS, Premera BCBS, Cigna, and more already cover Spravato, alone.
Our co-founder, Dr. Haviva Malina shared her enthusiasm about this milestone:
“We are thrilled with the FDA’s decision to approve Spravato as a monotherapy for treatment-resistant depression. This breakthrough simplifies the treatment process and offers rapid symptom improvement, enhancing our ability to support patients effectively. It’s a significant step forward in our mission to provide cutting-edge care.”
What This Means for You
Patients considering Spravato can soon take advantage of its benefits without needing to commit to daily oral antidepressants. This flexibility will be particularly appealing for those who prefer streamlined treatment options or have faced challenges with other medications in the past.
Learn More About Spravato
At Keta Medical Center, we’re dedicated to staying at the forefront of mental health advancements. If you or a loved one is struggling with treatment-resistant depression, contact us today to find out if Spravato can help you or your family member.
